The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.
The FDA has granted accelerated approval to IMDELLTRAâ„¢ for treating extensive-stage small cell lung cancer following platinum ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.
Lung Cancer is a complex and devastating disease with over 200,000 new cases in 2024 alone. Small Cell Lung Cancer, or SCLC, is one of the most aggressive cancers out there, ...